<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rsp</journal-id><journal-title-group><journal-title xml:lang="ru">Научно-практическая ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Rheumatology Science and Practice</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1995-4484</issn><issn pub-type="epub">1995-4492</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.47360/1995-4484-2021-93-96</article-id><article-id custom-type="elpub" pub-id-type="custom">rsp-2995</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL RESEARCH</subject></subj-group></article-categories><title-group><article-title>Качество жизни больных с алкаптонурией</article-title><trans-title-group xml:lang="en"><trans-title>Quality of life of patients with alkaptonuria</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1262-932X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кузин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kuzin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кузин Александр Васильевич</p><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1</p><p>115522, Москва, Каширское шоссе, 34а</p></bio><bio xml:lang="en"><p>Aleksander Kuzin</p><p>125993, Moscow, Barrikadnaya str., 2/1, building 1</p><p>115522, Moscow, Kashirskoye Highway, 34A</p><p> </p></bio><email xlink:type="simple">dr.a.kuzin@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5382-6357</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Амирджанова</surname><given-names>В. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Amirdzhanova</surname><given-names>V. N.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"><p>Vera N. Amirdzhanova</p><p>115522, Moscow, Kashirskoye Highway, 34A</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9092-9398</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Зайцева</surname><given-names>Е. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Zaytseva</surname><given-names>E. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1</p></bio><bio xml:lang="en"><p>Elena M. Zaytseva</p><p>125993, Moscow, Barrikadnaya str., 2/1, building 1</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4992-7953</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Долженкова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Dolzhenkova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>390039, Рязань, ул. Интернациональная, 3а</p></bio><bio xml:lang="en"><p>Elena A. Dolzhenkova</p><p>390039, Ryazan, Internationalnaya str., 3A</p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»<country>Россия</country></aff><aff xml:lang="en">Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation; V.A. Nasonova Research Institute of Rheumatology<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»<country>Россия</country></aff><aff xml:lang="en">V.A. Nasonova Research Institute of Rheumatology<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru">ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России<country>Россия</country></aff><aff xml:lang="en">Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru">ГБУ Рязанской области «Областная клиническая больница»<country>Россия</country></aff><aff xml:lang="en">Ryazan Regional Clinical Hospital<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>03</day><month>03</month><year>2021</year></pub-date><volume>59</volume><issue>1</issue><fpage>93</fpage><lpage>96</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кузин А.В., Амирджанова В.Н., Зайцева Е.М., Долженкова Е.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Кузин А.В., Амирджанова В.Н., Зайцева Е.М., Долженкова Е.А.</copyright-holder><copyright-holder xml:lang="en">Kuzin A.V., Amirdzhanova V.N., Zaytseva E.M., Dolzhenkova E.A.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://rsp.mediar-press.net/rsp/article/view/2995">https://rsp.mediar-press.net/rsp/article/view/2995</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования: изучить качество жизни больных алкаптонурией.</p></sec><sec><title>Материал и методы</title><p>Материал и методы. В исследование включено 50 пациентов с достоверным диагнозом алкаптонурия в возрасте от 18 до 78 лет (средний возраст – 58,2±10,8 года). Среди них преобладали мужчины (n=31; 62%), в большинстве случаев (98%) предъявлявшие жалобы на боли в суставах и/или позвоночнике. Впервые суставной синдром дебютировал в возрасте от 17 до 39 лет (средний возраст дебюта – 29,4±4,76 года). Длительность клинических проявлений заболевания до установления диагноза варьировала от 7 до 47 лет (в среднем 23,35±8,17 года). У 74% больных имелась группа инвалидности. В исследуемой когорте индекс массы тела (ИМТ) был несколько выше нормальных значений и составлял в среднем 28,18±4,95 кг/м2. Качество жизни пациентов исследовалось с использованием опросника EuroQol-5D (EQ-5D).</p></sec><sec><title>Результаты</title><p>Результаты. Качество жизни, соответствующее удовлетворительному состоянию здоровья по EQ-5D, отмечено у 56% больных. Значения индекса качества жизни (ИКЖ) у них были более 0,5. 22% пациентов имели 0&lt;ИКЖ≤0,5. В некоторых случаях выявлялся ИКЖ≤0. В группах с 0&lt;ИКЖ≤0,5 и 0,5&lt;ИКЖ≤1,0 выявлено незначительное преобладание мужчин (54,5 и 57,1% соответственно). В группе с ИКЖ≤0 эти различия были более отчетливыми, доля мужчин составляла 81,8% (p&lt;0,01). При сравнении данных этой группы с параметрами наиболее благополучных пациентов (0,5&lt;ИКЖ≤1,0) наблюдались статистически значимые различия по подвижности (р=0,018), уходу за собой (р=0,018), выполнению действий в повседневной жизни (р=0,003), боли и дискомфорту (р=0,003). ИКЖ пациентов с алкаптонурией отрицательно коррелировал с возрастом (r=–0,38; p&lt;0,01) и необходимостью пользоваться костылями (r=–0,58; р&lt;0,01). Эндопротезирование (как минимум одного крупного сустава) было проведено у половины (54%) больных.</p></sec><sec><title>Заключение</title><p>Заключение. У взрослых пациентов с алкаптонурией выявлено существенное ухудшение качества жизни, что в первую очередь обусловлено поражением позвоночника и крупных суставов с необходимостью проведения эндопротезирования у половины больных. ИКЖ оказался крайне низким, его медиана составляла 0,34 (0,02; 0,56) при норме 1. Наряду с традиционными инструментами оценки поражения суставов у пациентов с алкаптонурией представляется целесообразным применение опросника EQ-5D, отражающего различные параметры качества жизни: от возможности выполнять действия в повседневной жизни до выраженности боли и депрессии, что позволяет в режиме скрининга получать информацию о функциональных возможностях пациентов и разрабатывать индивидуальную тактику оказания медицинской помощи, в том числе проведения своевременного хирургического лечения.</p></sec></abstract><trans-abstract xml:lang="en"><p>The aim of the study was to study the quality of life of patients with alkaptonuria.</p><sec><title>Material and methods</title><p>Material and methods. The study included 50 patients with a reliable diagnosis of alkaptonuria aged 18 to 78 years (mean age 58.2±10.8 years). Among them, men predominated (n=31; 62%), in most cases (98%) complaining of pain in the joints and/or spine. For the first time, the articular syndrome debuted at the age of 17 to 39 years (average age of debut – 29.4±4.76 years). The duration of clinical manifestations of the disease before diagnosis ranged from 7 to 47 years (mean 23.35±8.17 years). 74% of patients had a disability group. In the study cohort, the body mass index (BMI) was slightly higher than normal values and averaged 28.18±4.95 kg/m2. The quality of life of patients was assessed using the EuroQol-5D questionnaire (EQ-5D).</p></sec><sec><title>Results</title><p>Results. The quality of life corresponding to a satisfactory state of health according to EQ-5D was observed in 56% of patients. Their quality-of-life index (LQI) values were more than 0.5. 22% of patients had 0&lt;LQI≤0.5. In some cases, LQI≤0 was detected. In groups with 0&lt;LQI≤0.5 and 0.5&lt;LQI≤1.0, a slight predominance of men was revealed (54.5 and 57.1%, respectively). In the group with LQI&lt;0, these differences were more pronounced, the proportion of men was 81.8% (p&lt;0.01). When comparing the data of this group with the parameters of the most prosperous patients (0.5&lt;LQI≤1.0), statistically significant differences were observed in mobility (p=0.018), personal care (p=0.018), performance of actions in everyday life (p=0.003), pain and discomfort (p=0.003). LQI of patients with alkaptonuria negatively correlated with age (r=–0.38; p&lt;0.01) and the need to use crutches (r=–0.58; p&lt;0.01). Endoprosthetics (at least one large joint) was performed in half (54%) of patients.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>алкаптонурия</kwd><kwd>охроноз</kwd><kwd>качество жизни</kwd><kwd>EQ-5D</kwd></kwd-group><kwd-group xml:lang="en"><kwd>alkaptonuria</kwd><kwd>ochronosis</kwd><kwd>quality of life</kwd><kwd>EQ-5D</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Zatkova A. An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis. 2011;34:1127−1136. doi: 10.1007/s10545-011-9363-z</mixed-citation><mixed-citation xml:lang="en">Zatkova A. An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis. 2011;34:1127−1136. doi: 10.1007/s10545-011-9363-z</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Taylor AM, Wlodarski B, Prior IA, Wilson PJM, Jarvis JC, Ranganath LR, et al. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology. 2010;49:1412−1414. doi: 10.1093/rheumatology/keq027</mixed-citation><mixed-citation xml:lang="en">Taylor AM, Wlodarski B, Prior IA, Wilson PJM, Jarvis JC, Ranganath LR, et al. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology. 2010;49:1412−1414. doi: 10.1093/rheumatology/keq027</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Phornphutkul C, Introne WJ, Perry MB, Berbardini I, Murphey MD, Fitzpatrick DL, et al. Natural history of alkaptonuria. Engl J Med. 2002;347:2111−2221. doi: 10.1056/NEJMoa021736</mixed-citation><mixed-citation xml:lang="en">Phornphutkul C, Introne WJ, Perry MB, Berbardini I, Murphey MD, Fitzpatrick DL, et al. Natural history of alkaptonuria. Engl J Med. 2002;347:2111−2221. doi: 10.1056/NEJMoa021736</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Башкова ИБ, Кичигин ВА, Безлюдная НВ, Степанов ЕГ, Ковалев ДВ, Карпухин АС, и др. Охроноз: трудности постановки диагноза в практике врача-клинициста. Трудный пациент. 2016;10–11:40−45.</mixed-citation><mixed-citation xml:lang="en">Bashkova IB, Kichigin VA, Bezluidnaya NV, Stepanov EG, Kovaliov DV, Karpukhin AS, et al. Ochronosis: Difficulties of diagnosis in the practice of a clinician. Trudnyy patsiyent = Difficult Patient. 2016;10–11:40–45 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ozmanevra R, Güran O, Karatosun V, Günal I. Total knee arthroplasty in ochronosis: A case report and critical review of the literature. Eklem Hastalik Cerrahisi. 2013;24:169−172. doi: 10.5606/ehc.2013.36</mixed-citation><mixed-citation xml:lang="en">Ozmanevra R, Güran O, Karatosun V, Günal I. Total knee arthroplasty in ochronosis: A case report and critical review of the literature. Eklem Hastalik Cerrahisi. 2013;24:169−172. doi: 10.5606/ehc.2013.36</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">The EuroQol group. EuroQol – a new facility for the measurement of health related quality of life. Health Policy. 1990;16:199−208. doi: 10.1016/0168-8510(90)90421-9</mixed-citation><mixed-citation xml:lang="en">The EuroQol group. EuroQol – a new facility for the measurement of health related quality of life. Health Policy. 1990;16:199−208. doi: 10.1016/0168-8510(90)90421-9</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Brooks R, the EuroQol Group. EuroQol: The current state of play. Health Policy. 1996,37:53−72. doi: 10.1016/0168-8510(96)00822-6</mixed-citation><mixed-citation xml:lang="en">Brooks R, the EuroQol Group. EuroQol: The current state of play. Health Policy. 1996,37:53−72. doi: 10.1016/0168-8510(96)00822-6</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: Results from a UK general population survey. Discussion paper. York: University of York; 1995:138.</mixed-citation><mixed-citation xml:lang="en">Dolan P, Gudex C, Kind P, Williams A. A social tariff for EuroQol: Results from a UK general population survey. Discussion paper. York: University of York; 1995:138.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Torrance G, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972;7:118−133.</mixed-citation><mixed-citation xml:lang="en">Torrance G, Thomas WH, Sackett DL. A utility maximization model for evaluation of health care programs. Health Serv Res. 1972;7:118−133.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337−343. doi: 10.3109/07853890109002087</mixed-citation><mixed-citation xml:lang="en">Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337−343. doi: 10.3109/07853890109002087</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Амирджанова ВН, Эрдес ШФ. Валидация русской версии общего опросника EuroQol-5D (EQ-5D). Научно-практическая ревматология. 2007;45(3):69−76. doi: 10.14412/1995-4484-2007-691</mixed-citation><mixed-citation xml:lang="en">Amirdjanova VN, Erdes SF. Validation of general questionnaire EuroQol-5D (EQ-5D). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2007;45(3):69−76 (In Russ.). doi: 10.14412/1995-4484-2007-691</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Perry MB, Suwannarat P, Furst GP, Gahl WA, Gerber LH. Musculoskeletal findings and disability in alkaptonuria. J Rheumatol. 2006;33(11):2280−2285.</mixed-citation><mixed-citation xml:lang="en">Perry MB, Suwannarat P, Furst GP, Gahl WA, Gerber LH. Musculoskeletal findings and disability in alkaptonuria. J Rheumatol. 2006;33(11):2280−2285.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cox TF, Psarelli EE, Taylor S, Shepherd HR, Robinson M, Barton G, et al. Subclinical ochronosis features in alkaptonuria: A cross-sectional study. BMJ Innovations. 2019;5(2-3):82−91. doi: 10.1136/bmjinnov-2018-000324</mixed-citation><mixed-citation xml:lang="en">Cox TF, Psarelli EE, Taylor S, Shepherd HR, Robinson M, Barton G, et al. Subclinical ochronosis features in alkaptonuria: A cross-sectional study. BMJ Innovations. 2019;5(2-3):82−91. doi: 10.1136/bmjinnov-2018-000324</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Rudebeck M, Scott C, Sireau N, Ranganath L. A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care. JIMD Reports. 2020;53:71−79. doi: 10.1002/jmd2.12101</mixed-citation><mixed-citation xml:lang="en">Rudebeck M, Scott C, Sireau N, Ranganath L. A patient survey on the impact of alkaptonuria symptoms as perceived by the patients and their experiences of receiving diagnosis and care. JIMD Reports. 2020;53:71−79. doi: 10.1002/jmd2.12101</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Spiga O, Cicaloni V, Fiorini C, Trezza A, Visibelli A, Millucci L, et al. Machine learning application for development of a data-driven predictive model able to investigate quality of life scores in a rare disease. Orphanet J Rare Dis. 2020;15:46. doi: 10.1186/s13023-020-1305-0</mixed-citation><mixed-citation xml:lang="en">Spiga O, Cicaloni V, Fiorini C, Trezza A, Visibelli A, Millucci L, et al. Machine learning application for development of a data-driven predictive model able to investigate quality of life scores in a rare disease. Orphanet J Rare Dis. 2020;15:46. doi: 10.1186/s13023-020-1305-0</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gallagher JA, Dillon JP, Sireau N, Timmis O, Ranganath LR. Alkaptonuria: An example of a fundamental disease – a rare disease with important lessons for more common disorders. Semin Cell Dev Biol. 2016;52:53−57. doi: 10.1016/j.sem-cdb.2016.02.020</mixed-citation><mixed-citation xml:lang="en">Gallagher JA, Dillon JP, Sireau N, Timmis O, Ranganath LR. Alkaptonuria: An example of a fundamental disease – a rare disease with important lessons for more common disorders. Semin Cell Dev Biol. 2016;52:53−57. doi: 10.1016/j.sem-cdb.2016.02.020</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Pathak SK, Kumar N, Bagtharia P. Alkaptonuria and multilevel intervertebral disc calcification. Joint Bone Spine. 2020;87(3):259. doi: 10.1016/j.jbspin.2020.01.004</mixed-citation><mixed-citation xml:lang="en">Pathak SK, Kumar N, Bagtharia P. Alkaptonuria and multilevel intervertebral disc calcification. Joint Bone Spine. 2020;87(3):259. doi: 10.1016/j.jbspin.2020.01.004</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
